Bernstein Remains Bullish on Eli Lilly and Company (LLY) With an $1,100 PT

Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to buy now. In a report released on July 8, Courtney Breen from Bernstein maintained a Buy rating on Eli Lilly and Company (NYSE:LLY) with a price target of $1,100.00.

Was Jim Cramer Right About Eli Lilly and Company (LLY)?

On July 9, Eli Lilly and Company (NYSE:LLY) reported that the US Food and Drug Administration (FDA) approved a label update with a new recommended titration dosing schedule for Kisunla. Kisunla is the company’s once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer’s disease (AD).

The TRAILBLAZER-ALZ 6 study showed that the modified titration schedule considerably reduced the occurrence of “amyloid-related imaging abnormalities with edema/effusion (ARIA-E) versus the original dosing schedule at 24 and 52 weeks, while still achieving similar levels of amyloid plaque removal and P-tau217 reduction”.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

While we acknowledge the potential of LLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.